Chimeric Therapeutics Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net income was AUD 2.44 million compared to net loss of AUD 11.75 million a year ago. Basic earnings per share from continuing operations was AUD 0.0044 compared to basic loss per share from continuing operations of AUD 0.0275 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.029 AUD | +7.41% | 0.00% | -17.14% |
02:38am | Chimeric Therapeutics Appoints COO; Shares Rise 4% | MT |
May. 01 | Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20% | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.14% | 16.59M | |
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023